PCVX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat CEL-SCI's return on equity of --.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 247.28%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 5961.21%. Given that CEL-SCI has higher upside potential than Vaxcyte, analysts believe CEL-SCI is more attractive than Vaxcyte.

Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Vaxcyte's net income of -$140.7M is lower than CEL-SCI's net income of -$6.6M. Notably, Vaxcyte's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Vaxcyte's net margin of -711.67%. Vaxcyte's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 247.28%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 979.39%. Given that IGC Pharma has higher upside potential than Vaxcyte, analysts believe IGC Pharma is more attractive than Vaxcyte.

Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Vaxcyte's net income of -$140.7M is lower than IGC Pharma's net income of -$1.8M. Notably, Vaxcyte's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 21.61x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Vaxcyte's net margin of 32.71%. Vaxcyte's return on equity of -- beat Merck &'s return on equity of 39.02%.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 247.28%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 27.3%. Given that Vaxcyte has higher upside potential than Merck &, analysts believe Vaxcyte is more attractive than Merck &.

Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4% to investors and pays a quarterly dividend of $0.81 per share. Vaxcyte pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vaxcyte quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Vaxcyte's net income of -$140.7M is lower than Merck &'s net income of $5.1B. Notably, Vaxcyte's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 3.17x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Vaxcyte's net margin of 21.63%. Vaxcyte's return on equity of -- beat Pfizer's return on equity of 8.72%.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 247.28%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 19.45%. Given that Vaxcyte has higher upside potential than Pfizer, analysts believe Vaxcyte is more attractive than Pfizer.

Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.95% to investors and pays a quarterly dividend of $0.43 per share. Vaxcyte pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Vaxcyte's net income of -$140.7M is lower than Pfizer's net income of $3B. Notably, Vaxcyte's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 2.23x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.